Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome

Muscle and Nerve

Volumn 23, Issue 7, 2000, Pages 1051-1056

  Hashiguchi, Teruto ^a   Arimura, Kimiyoshi ^a   Matsumuro, Kenji ^a   Otsuka, Reika ^a   Watanabe, Osamu ^a   Jonosono, Manabu ^a   Maruyama, Yoshikazu ^a   Maruyama, Ikuro ^a   Osame, Mitsuhiro ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Coagulation; Crow Fukase syndrome; Platelet; POEMS syndrome; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CASE REPORT; CROW FUKASE SYNDROME; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; AGED; ANTI-INFLAMMATORY AGENTS; BLOOD PLATELETS; CALCIUM; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOKINES; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET COUNT; POEMS SYNDROME; THROMBIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033932748     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-4598(200007)23:7<1051::AID-MUS7>3.0.CO;2-V     Document Type: Article

References (29)

1. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956-964.
2. Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine 1980;59:311-322.
3. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87:3336-3343.
4. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535-1545.
5. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996;271:17629-17634.
6. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-1478.
7. Crow RS. Peripheral neuritis in myelomatosis. Br Med J 1956; 2:802-804.
8. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-858.
9. Fukase M, Shimpo S, Nishitani H, Tsunematu T. Solitary plasmacytoma produced polyneuropathy and endocrine abnormalities. Nippon Rinsho 1968;26:2444-2456.
10. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-1312.
11. Lesprit P, Authier FJ, Gherardi R, Belec L, Paris D, Melliere D, Schaeffer A, Godeau B. Acute arterial obliteration: a new feature of the POEMS syndrome? Medicine 1996;75:226-232.
12. Lesprit P, Godeau B, Authier FJ, Soubrier M, Zuber M, Larroche C, Viard JP, Wechsler B, Gherardi R. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med 1998;157:907-911.
13. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
14. Luo JC, Yamaguchi S, Shinkai A, Shitara K, Shibuya M. Significant expression of vascular endothelial growth factor/ vascular permeability factor in mouse ascites tumors. Cancer Res 1998;58:2652-2660.
15. Maloney JP, Silliman CC, Ambruso DR, Wang J, Tuder RM, Voelkel NF. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 1998;275: H1054-H1061.
16. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Consttutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997;94:663-668.
17. Montrucchio G, Brizzi MF, Calosso G, Marengo S, Pegoraro L, Camussi G. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996;87:2762-2768.
18. Nakahara K, Hoketsu Y, Sano Y, Shinmyozu K, Igata A. Improvement of parameters concerning blood coagulation and complement systems in a case of Crow-Fukase syndrome. Clin Neurol (Jpn) 1985;25:755-759.
19. Nakanishi T, Sobue I, Toyokura Y, Nishitani H, Kuroiwa Y, Satoyoshi E, Tsubaki T, Igata A, Ozaki Y. The Crow - Fukase syndrome: a study of 102 cases in Japan. Neurology 1984;34: 712-720.
20. Nishi J, Arimura K, Utsunomiya A, Yonezawa S, Kawakami K, Maeno N, Ijichi O, Ikarimoto N, Nakata M, Kitajima I, Fukushige T, Takamatsu H, Miyata K, Maruyama I. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol 1999;104:482-485.
21. Ribadeau DS, Tillie LI, Rose C, Saulnier F, Wemeau JL, Hatron PY, Wallaert B. Pulmonary hypertension associated with POEMS syndrome. Eur Respir J 1996; 9:1760-1762.
22. Saida K, Kawakami H, Ohta M, Iwamura K. Coagulation and vascular abnormalities in Crow-Fukase syndrome. Muscle Nerve 1997;20:486-492.
23. Sano H, Terano T, Nakumo K. Beneficial treatment of argatroban on polyneuropathy associated with Crow-Fukase syndrome. A case report. Neurol Treat (Jpn) 1993;10: 121-125.
24. Soubrier M, Dubost JJ, Serre AF, Ristori JM, Sauvezie B, Cathebras P, Piette JC, Chapman A, Authier FJ, Gherardi RK. Growth factors in POEMS syndrome: evidence for marked increase in circulating vascular endothelial growth factor. Arthritis Rheum 1997;40:786-787.
25. Soubrier M, Guillon R, Dubost JJ, Serre AF, Ristori JM, Boyer L, Sauvezie B. Arterial obliteration in POEMS syndrome: possible role of vascular endothelial growth factor. J Rheumatol 1998;25:813-815.
26. Takatsuki K, Sanada I. Plasma cell dyscrasia with polyneuropathy and endocrine disorders: clinical and laboratory features of 109 reported cases. Jpn J Clin Oncol 1983;13:543-556.
27. Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 1996;347:702.
28. Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, Matsuo K, Arisato T, Osame M. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 1998;21:1390-1397.
29. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci Colch 1998; 94:395-404.